Future Focus: Gastrointestinal Stromal Tumor

Full Title: Future Focus: Gastrointestinal Stromal Tumor - The Current and Future U.S. Market for Gastrointestinal Stromal Tumor (GIST)

Free Bonus Reports

When you invest in the GIST report you may pick any 10 Cancer Highlights reports from this list for free (Value: $26,000 USD)

Gastrointestinal stromal tumor (GIST) has long been known as a tumor that arises from mesenchymal cells of the gastrointestinal tract but only in the past decade has its true histological nature become apparent. Following the identification of KIT mutations as a major driving force in the tumorigenesis of this disease, treatment of GIST has been significantly improved, primarily through the approval of Gleevec® (imatinib mesylate). However, with the approval of Sutent® (sunitinib malate), a new option exists for the patients who develop resistance to Gleevec. GIST is becoming an increasingly visible and growing disease that is not well covered by existing data sources.

This unique new report was produced to provide companies with an impartial assessment of the current population and clinical landscape of GIST. This report reviews the current medical and market climates for GIST and assesses future treatment(s) and potential opportunities arising from market evolution.

Unique Features

• Forward-looking review and analysis of the rapidly evolving GIST drug market in the United States
• Best available epidemiology using rigorous MattsonJack DaVinci modeling
• Illumination of prospects for new drug development for treating GIST patients
• Practicing physician opinion on current treatment and use of new therapies for these diseases
• Projections of the GIST market based on primary and secondary information with forecasts through 2015

Client Benefits

Marketing management, product managers, and market research analysts in both major pharmaceutical and biotech companies will find this report invaluable for scoping the size of the current and future GIST market; sales forecasting new products; and successful strategic planning and business development opportunities in the future GIST market. Our report will enable you to:

• Be abreast of thought-leader and community physician opinion. Use our independent assessments to validate or challenge in-house assumptions
• Count on MattsonJack DaVinci’s tested epidemiology and market models to provide the background and direction you need
• Tap the expertise of dedicated MattsonJack DaVinci researchers and consultants
• Stay ahead of the curve regarding this rapidly developing market

Research Approach

MattsonJack DaVinci relies heavily on primary research, including extensive interviews, surveys, internal modeling, and analysis:

• Treatment architecture and emerging trend survey
• Attendance at key oncology meetings with comprehensive literature review from proceedings
• Computer modeling, including expert access and manipulation of SEER data sets
• Extensive analysis leveraging the expertise of team members and outside thought-leaders

Deliverables and Services

• Two (2) copies of the report, contained in 3-ring binders
• Electronic delivery on CD-ROM (2)
• Detailed population data sheets provided in Excel
• Access to other MattsonJack DaVinci models upon request
• Above all, MattsonJack DaVinci stands by its research and findings and strives to provide quality service to our client sponsors
• 6 hours of telephone or e-mail access to our research team. Inquiries are billed against client budget in 15-minute increments

Features

• Skilled quantification analyses
• Patient-based, "bottomup" modeling
• Primary research
• Experienced staff
• Access to research team via a responsive inquiry service

Chapter I: Methodologies

To insure complete understanding of the processes, assumptions, and models utilized in this report, the first chapter details the methodologies utilized for each chapter:

• Description of epidemiology modeling
• Overview of the surves undertaken for this report
• Review of MattsonJack DaVinci’s Emerging Technology process
• Description of our Oncology Market Model used to estimate the current and future U.S. GIST market

Chapter II: Disease Background

Provides a review of GIST including the staging system and a review of survival/prognosis

Chapter III: Patient Populations

MattsonJack DaVinci uses our extensive epidemiology modeling experience to review the available GIST epidemiology research and develop a model for the U.S. market:

• Provides incidence and prevalence
• Advanced epidemiology looking at treated populations
• Better identifies "actively" treated patients through the clinical flow using updated models
• Presents population estimates and projects treated populations from 2005 through 2025

Chapter IV: Treatment Architecture

This chapter evaluates how GIST patients are diagnosed and treated in today’s clinical environment. Our updated, enhanced analysis:

• Description of the therapeutic options including new agents like Sutent®
• Treatment data from our primary research

Chapter V: Emerging Technologies

MattsonJack DaVinci provides a review of key products on the market and in development for the management of GIST, including:

• AMG-706
• AMN-107
• AG-013736
• Nexavar®
• PCK412
• PTK787
• BMS 354825 (dasatinib)

Chapter VI: Market Perspectives

Quantifies the current and potential future U.S. GIST market utilizing MattsonJack DaVinci’s Oncology Market Model process:

• Reviews the current GIST market for previous (2006) and current year (2007)
• Provides value for supportive care and therapeutic products
• Conducts a future market evolution estimate using the current marketplace and the Emerging Technology model from 2005 through 2015

Chapter V: Future Perspectives

Provides a top-line review of key issues for the future of the U.S. GIST market given the rapid market evolution expected with the recent approval of Sutent®

Table of Contents

Download TOC in PDF